Let’s talk about NASH – The pharma opportunity everyone’s waiting for

The race to treat NASH. Several promising candidates are currently competing in a multi-billion-dollar race. NASH, or non-alcoholic steatohepatitis, affects millions of patients world-wide and by 2020 is projected to replace hepatitis C as the number one reason for liver transplantation in the United States.

Multiple drug developers have taken on the challenge and a variety of different approaches are currently in the pipeline to tackle this complex, silent disease. Now all eyes are on the finish line to see who will be the first to enter this lucrative and untapped market.

Understanding the bigger picture of NAFLD

Non-alcoholic fatty liver disease (NAFLD) is an umbrella of disorders characterized by the accumulation of excess fat in the liver of people who drink little or no alcohol. NAFLD is the most common chronic liver condition in the world with a global prevalence estimated to be 25.2.%4 In the United States, NAFLD is the most common form of chronic liver disease, affecting about one-quarter of the population. In 2017 the direct lifetime costs associated with NAFLD were $222.6 billion; $95.4 billion of this was just for patients with an advanced form of liver disease known as non-alcoholic steatohepatitis or NASH.

Who is at risk?

A wide range of diseases and conditions can increase the risk of NAFLD including obesity, type 2 diabetes, hypertriglyceridemia, insulin resistance, and hypertension. In fact, studies have shown that NAFLD may be present in up to 70% of patients with diabetes.

What is NASH?

Up to 30% of people with NAFLD will develop NASH, a more progressive type of liver disease. NASH is associated with hepatocellular ballooning and inflammation, in addition to hepatic steatosis. About 20% of people with NASH will go on to develop scarring (fibrosis) of the liver, which may become severe enough to affect the liver’s function, conferring an increased risk of liver cirrhosis or liver cancer. Overall, the global prevalence of NASH is estimated to be 1.5%-6.5% and it is predicted to become the leading indication for liver transplantation in the next few years.

NASH White Paper From Deallus
DOWNLOAD WHITE PAPER

You may also be interested in…

CARe To Understand What Will Shape CAR T’s Future?

CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.

  • COVID-19-Ondemand-Webinar Leading in a Crisis

OnDemand Webinar – Leading in a crisis

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussion series on Navigating Market Disruption. Episode two is Leading in a crisis. Rita and Pete will discuss why focus and remaining agile during and after a crisis are essential for success. Executives looking for practical advice on how to balance agility and governance processes will find this discussion valuable.

  • Deallus Announce New Senior Principal

Kevin Bibby joins Deallus as Senior Principal

We are very pleased to welcome Kevin Bibby to our Deallus team as Senior Principal. Kevin brings extensive expertise in commercial strategy to the fold, as well as a deep background in brand and portfolio strategy, product positioning, and workshop facilitation. We look forward to adding his knowledge, skill sets, and collaborative spirit to the team.

  • Leading in a Crisis: Driving Value for Your Customers, Your Organization, and Yourself

Episode 2: Leading in a crisis

Join Peter Hempshall, Deallus CEO, and Rita Numerof, President of Numerof & Associates for Episode 2 of their discussion series - Leading in a crisis. This episode will explore topics around how leaders can manage effectively during a crisis and continue to deliver value for their customers, their organizations, and for themselves. Any business leader eager to explore tactics, best practices, and learning experiences gained from leading in times of uncertainty will find value in this episode.

To learn more about this topic, or to find out about ways in which Deallus can help you, please get in touch.

For any questions or comments on this thought piece, please reach out to Julie Munch Khan - Deallus Chief Commercial Officer

Julie Munch Khan – Deallus Chief Commercial Officer